The FDA has accepted a brand-new drug application for Xelpros to minimize IOP (intra-ocular pressure) in open-angle glaucoma as well as eye high blood pressure. Sunlight Pharmaceutical Industries as well as Sunlight Pharma Advanced Research Company introduced the new drug-application in a joint news release.
Xelpros (latanoprost ophthalmic service 0.005%) is the first latanoprost item not created with the preservative benzalkonium chloride and also was established with SPARC’s Swollen Micelle Microemulsion technology, the release stated.
It was shown to minimize IOP in clients with open-angle glaucoma and ocular high blood pressure, approximately a mean of 6 mm Hg to 8 mm Hg in randomized scientific tests.
“As the only BAK-free variation of latanoprost, Xelpros will be an important and alternate treatment alternative for people with open-angle glaucoma or ocular high blood pressure,” Sunlight Pharma North America CEO Abhay Gandhi stated in the release. Sun Ophthalmics will market Xelpros in the USA.